Your session is about to expire
← Back to Search
Genetically Modified T cells for Leukemia and Lymphoma
Study Summary
This trial is testing the safety of giving patients modified T-cells from a donor. The goal is to see if these cells cause any toxicities in patients with relapsed B cell leukemia or lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have health issues that make it hard for me to handle side effects.My cancer has returned and tests show more than 5% cancer cells in my bone marrow or any cancer presence detected by specific tests.My cancer returned after a stem cell or organ transplant.My age does not limit my participation.I am an adult with a heart condition.I have a history of CD19+ cancer, like Non-Hodgkin Lymphoma, and might need a stem cell transplant.I have an active HIV, hepatitis B, or hepatitis C infection.I do not have any uncontrolled illnesses causing symptoms.I haven't had chemotherapy in the last 2 weeks.My liver tests are within the required limits.I am not currently receiving treatment for any other cancer besides the one being studied.I am currently receiving steroids for active graft versus host disease or autoimmune disease.I can do most of my daily activities by myself.My kidney function is normal, with creatinine levels within the required range.My condition is worsening quickly and may prevent me from completing the treatment.I have had active brain leukemia in the last 28 days.My heart's pumping ability is at least 40%.My leukemia has returned outside the bone marrow.
- Group 1: Biological/Genetically Modified T cells
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What diseases have been addressed successfully through utilizing modified T cells?
"Biologically or genetically modified T cells can be highly effective at treating multiple sclerosis, as well as a plethora of other illnesses such leukemia, myelocytic acute lymphoblastic leukemia, mixed cell type lymphoma, and retinoblastoma."
Are Biological/Genetically Modified T cells allowed by the FDA?
"Limited data on Biological/Genetically Modified T cells' effectiveness and safety resulted in a score of 1."
Are there available slots in this clinical trial for participants?
"Based on the information from clinicaltrials.gov, this particular medical trial has now concluded its recruitment process. The study was posted in September 2011 and last updated in August 2022; nevertheless, there are still 2904 other studies actively looking for participants at present."
What is the ceiling for participants in this medical experiment?
"At present, this trial is closed for recruitment. It was first advertised on September 1st 2011 and the last update occurred on August 31st 2022. Alternately, there are 2088 trials actively searching for lymphoma patients and 816 studies utilizing Biological/Genetically Modified T cells that are currently enrolling participants."
Has research into Biological/Genetically Modified T cells been explored in the past?
"At present, 816 active studies related to Biological/Genetically Modified T cells are in the process of recruitment with 154 trials at Phase 3. Although most of these clinical trials occur within Philadelphia, Pennsylvania, 27827 locations across the United States have begun enrolling patients for research on Biological/Genetically Modified T cells."
Share this study with friends
Copy Link
Messenger